Global Fertility Testing Market

Fertility Testing Comprehensive Study by Type (Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound), Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)), End User (Hospital, Speciality Clinics, Medical Store, Others) Players and Region - Global Market Outlook to 2030

Fertility Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fertility Testing
Fertility testing is the first step in the treatment of infertility. It is used for the detection of ovules or to diagnose infertility, an inability to reproduce by natural means. Fertility testing involves a medical history, ovulation or menstrual cycle issues, blood tests, scrotal ultrasound, hormone testing, and many more, and fertility tests have kits for diagnosis as well. Technological advancements in fertility testing methods and devices have improved accuracy, accessibility, and convenience. This includes home fertility testing kits, wearable devices, and improvements in laboratory testing methods.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The fertility testing market experiencing competition among various companies offering a range of products and services. It's important to note that the competitive landscape may have evolved since then, so it's recommended to check the latest industry reports, news sources, and company updates for the most current information. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck KGaA (Germany), Abbott (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Beckman Coulter, Inc. (United States), bioMerieux (France), Church and Dwight (New Jersey), DCC (Dubai), Geratherm Medical (Germany), Germaine Laboratories (United States), Kent Pharmaceuticals (India), Swiss Precision Diagnostics (China), Carrot (United States), QIAGEN (Netherland), Arva Health (India) and Ro (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Fertility Testing market by and Region.



On the basis of geography, the market of Fertility Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Type, the sub-segment i.e. Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound) will boost the Fertility Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Fertility Testing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased used of home-based fertility testing

Market Growth Drivers:
Growing awareness regarding fertility issues and Factors such as lifestyle changes, environmental factors, and health issues have contributed to an increase in infertility rates, leading to a higher demand for fertility testing

Challenges:
Stringent regulations and approval processes for fertility testing products and treatments can slow down innovation and market entry.

Restraints:
High Cost of Fertility Treatments and Insurance coverage for fertility treatments is limited

Opportunities:
Integration in technology, such as the integration of artificial intelligence and machine learning in fertility prediction algorithms and The rise of telehealth services may lead to increased accessibility to fertility testing and consultations,

Market Leaders and their expansionary development strategies
In May 2021, Digital health company Ro is adding reproductive health to its growing platform with plans to acquired Modern Fertility. The acquisition significantly expands Ro's women's health offering, adding Modern Fertility to the company's vertically integrated primary care platform.
In December 2023, An India-based modern reproductive clinic for women and offers hormone-focused diagnostic tests for Fertility, Infertility, PCOS, PCOD, and Thyroid Health Arva Health, has launched an at-home fertility test to help women track and monitor their hormones. The test aims to help women with polycystic ovary syndrome and thyroid issues understand their reproductive health and In December 2021, Carrot Fertility, the leading global fertility healthcare and family-forming benefits provider for employers and health plans, launched new capabilities for members to perform at-home fertility hormone and related biomarker monitoring.


Key Target Audience
Research organization, Government Regulatory, End-User Industry and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound)
  • Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)

By End User
  • Hospital
  • Speciality Clinics
  • Medical Store
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing awareness regarding fertility issues
      • 3.2.2. Factors such as lifestyle changes, environmental factors, and health issues have contributed to an increase in infertility rates, leading to a higher demand for fertility testing
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulations and approval processes for fertility testing products and treatments can slow down innovation and market entry.
    • 3.4. Market Trends
      • 3.4.1. Increased used of home-based fertility testing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fertility Testing, by Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fertility Testing (Value)
      • 5.2.1. Global Fertility Testing by: Type (Value)
        • 5.2.1.1. Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound)
        • 5.2.1.2. Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)
      • 5.2.2. Global Fertility Testing by: Type (Value)
        • 5.2.2.1. Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound)
        • 5.2.2.2. Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)
      • 5.2.3. Global Fertility Testing by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Speciality Clinics
        • 5.2.3.3. Medical Store
        • 5.2.3.4. Others
      • 5.2.4. Global Fertility Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Fertility Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens Healthineers AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Beckman Coulter, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioMerieux (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Church and Dwight (New Jersey)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. DCC (Dubai)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Geratherm Medical (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Germaine Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Kent Pharmaceuticals (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Swiss Precision Diagnostics (China)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Carrot (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. QIAGEN (Netherland)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Arva Health (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Ro (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Fertility Testing Sale, by Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fertility Testing (Value)
      • 7.2.1. Global Fertility Testing by: Type (Value)
        • 7.2.1.1. Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound)
        • 7.2.1.2. Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)
      • 7.2.2. Global Fertility Testing by: Type (Value)
        • 7.2.2.1. Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound)
        • 7.2.2.2. Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis)
      • 7.2.3. Global Fertility Testing by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Speciality Clinics
        • 7.2.3.3. Medical Store
        • 7.2.3.4. Others
      • 7.2.4. Global Fertility Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fertility Testing: by Type(USD Million)
  • Table 2. Fertility Testing Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound) , by Region USD Million (2018-2023)
  • Table 3. Fertility Testing Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis) , by Region USD Million (2018-2023)
  • Table 4. Fertility Testing: by Type(USD Million)
  • Table 5. Fertility Testing Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound) , by Region USD Million (2018-2023)
  • Table 6. Fertility Testing Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis) , by Region USD Million (2018-2023)
  • Table 7. Fertility Testing: by End User(USD Million)
  • Table 8. Fertility Testing Hospital , by Region USD Million (2018-2023)
  • Table 9. Fertility Testing Speciality Clinics , by Region USD Million (2018-2023)
  • Table 10. Fertility Testing Medical Store , by Region USD Million (2018-2023)
  • Table 11. Fertility Testing Others , by Region USD Million (2018-2023)
  • Table 12. South America Fertility Testing, by Country USD Million (2018-2023)
  • Table 13. South America Fertility Testing, by Type USD Million (2018-2023)
  • Table 14. South America Fertility Testing, by End User USD Million (2018-2023)
  • Table 15. Brazil Fertility Testing, by Type USD Million (2018-2023)
  • Table 16. Brazil Fertility Testing, by End User USD Million (2018-2023)
  • Table 17. Argentina Fertility Testing, by Type USD Million (2018-2023)
  • Table 18. Argentina Fertility Testing, by End User USD Million (2018-2023)
  • Table 19. Rest of South America Fertility Testing, by Type USD Million (2018-2023)
  • Table 20. Rest of South America Fertility Testing, by End User USD Million (2018-2023)
  • Table 21. Asia Pacific Fertility Testing, by Country USD Million (2018-2023)
  • Table 22. Asia Pacific Fertility Testing, by Type USD Million (2018-2023)
  • Table 23. Asia Pacific Fertility Testing, by End User USD Million (2018-2023)
  • Table 24. China Fertility Testing, by Type USD Million (2018-2023)
  • Table 25. China Fertility Testing, by End User USD Million (2018-2023)
  • Table 26. Japan Fertility Testing, by Type USD Million (2018-2023)
  • Table 27. Japan Fertility Testing, by End User USD Million (2018-2023)
  • Table 28. India Fertility Testing, by Type USD Million (2018-2023)
  • Table 29. India Fertility Testing, by End User USD Million (2018-2023)
  • Table 30. South Korea Fertility Testing, by Type USD Million (2018-2023)
  • Table 31. South Korea Fertility Testing, by End User USD Million (2018-2023)
  • Table 32. Taiwan Fertility Testing, by Type USD Million (2018-2023)
  • Table 33. Taiwan Fertility Testing, by End User USD Million (2018-2023)
  • Table 34. Australia Fertility Testing, by Type USD Million (2018-2023)
  • Table 35. Australia Fertility Testing, by End User USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Fertility Testing, by Type USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Fertility Testing, by End User USD Million (2018-2023)
  • Table 38. Europe Fertility Testing, by Country USD Million (2018-2023)
  • Table 39. Europe Fertility Testing, by Type USD Million (2018-2023)
  • Table 40. Europe Fertility Testing, by End User USD Million (2018-2023)
  • Table 41. Germany Fertility Testing, by Type USD Million (2018-2023)
  • Table 42. Germany Fertility Testing, by End User USD Million (2018-2023)
  • Table 43. France Fertility Testing, by Type USD Million (2018-2023)
  • Table 44. France Fertility Testing, by End User USD Million (2018-2023)
  • Table 45. Italy Fertility Testing, by Type USD Million (2018-2023)
  • Table 46. Italy Fertility Testing, by End User USD Million (2018-2023)
  • Table 47. United Kingdom Fertility Testing, by Type USD Million (2018-2023)
  • Table 48. United Kingdom Fertility Testing, by End User USD Million (2018-2023)
  • Table 49. Netherlands Fertility Testing, by Type USD Million (2018-2023)
  • Table 50. Netherlands Fertility Testing, by End User USD Million (2018-2023)
  • Table 51. Rest of Europe Fertility Testing, by Type USD Million (2018-2023)
  • Table 52. Rest of Europe Fertility Testing, by End User USD Million (2018-2023)
  • Table 53. MEA Fertility Testing, by Country USD Million (2018-2023)
  • Table 54. MEA Fertility Testing, by Type USD Million (2018-2023)
  • Table 55. MEA Fertility Testing, by End User USD Million (2018-2023)
  • Table 56. Middle East Fertility Testing, by Type USD Million (2018-2023)
  • Table 57. Middle East Fertility Testing, by End User USD Million (2018-2023)
  • Table 58. Africa Fertility Testing, by Type USD Million (2018-2023)
  • Table 59. Africa Fertility Testing, by End User USD Million (2018-2023)
  • Table 60. North America Fertility Testing, by Country USD Million (2018-2023)
  • Table 61. North America Fertility Testing, by Type USD Million (2018-2023)
  • Table 62. North America Fertility Testing, by End User USD Million (2018-2023)
  • Table 63. United States Fertility Testing, by Type USD Million (2018-2023)
  • Table 64. United States Fertility Testing, by End User USD Million (2018-2023)
  • Table 65. Canada Fertility Testing, by Type USD Million (2018-2023)
  • Table 66. Canada Fertility Testing, by End User USD Million (2018-2023)
  • Table 67. Mexico Fertility Testing, by Type USD Million (2018-2023)
  • Table 68. Mexico Fertility Testing, by End User USD Million (2018-2023)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Company Basic Information, Sales Area and Its Competitors
  • Table 85. Fertility Testing: by Type(USD Million)
  • Table 86. Fertility Testing Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound) , by Region USD Million (2025-2030)
  • Table 87. Fertility Testing Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis) , by Region USD Million (2025-2030)
  • Table 88. Fertility Testing: by Type(USD Million)
  • Table 89. Fertility Testing Women (Medical history assessment, Sonogram, Hormone blood tests, Ovarian reserve test, Sonohysterogram, Hysterosalpingogram, Hysteroscopy, Ultrasound) , by Region USD Million (2025-2030)
  • Table 90. Fertility Testing Men (Medical History Assessment, Semen Analysis, Genetic Testing, Hormone Levels Blood Test, Scrotal Ultrasound, Post Ejaculatory Urinalysis) , by Region USD Million (2025-2030)
  • Table 91. Fertility Testing: by End User(USD Million)
  • Table 92. Fertility Testing Hospital , by Region USD Million (2025-2030)
  • Table 93. Fertility Testing Speciality Clinics , by Region USD Million (2025-2030)
  • Table 94. Fertility Testing Medical Store , by Region USD Million (2025-2030)
  • Table 95. Fertility Testing Others , by Region USD Million (2025-2030)
  • Table 96. South America Fertility Testing, by Country USD Million (2025-2030)
  • Table 97. South America Fertility Testing, by Type USD Million (2025-2030)
  • Table 98. South America Fertility Testing, by End User USD Million (2025-2030)
  • Table 99. Brazil Fertility Testing, by Type USD Million (2025-2030)
  • Table 100. Brazil Fertility Testing, by End User USD Million (2025-2030)
  • Table 101. Argentina Fertility Testing, by Type USD Million (2025-2030)
  • Table 102. Argentina Fertility Testing, by End User USD Million (2025-2030)
  • Table 103. Rest of South America Fertility Testing, by Type USD Million (2025-2030)
  • Table 104. Rest of South America Fertility Testing, by End User USD Million (2025-2030)
  • Table 105. Asia Pacific Fertility Testing, by Country USD Million (2025-2030)
  • Table 106. Asia Pacific Fertility Testing, by Type USD Million (2025-2030)
  • Table 107. Asia Pacific Fertility Testing, by End User USD Million (2025-2030)
  • Table 108. China Fertility Testing, by Type USD Million (2025-2030)
  • Table 109. China Fertility Testing, by End User USD Million (2025-2030)
  • Table 110. Japan Fertility Testing, by Type USD Million (2025-2030)
  • Table 111. Japan Fertility Testing, by End User USD Million (2025-2030)
  • Table 112. India Fertility Testing, by Type USD Million (2025-2030)
  • Table 113. India Fertility Testing, by End User USD Million (2025-2030)
  • Table 114. South Korea Fertility Testing, by Type USD Million (2025-2030)
  • Table 115. South Korea Fertility Testing, by End User USD Million (2025-2030)
  • Table 116. Taiwan Fertility Testing, by Type USD Million (2025-2030)
  • Table 117. Taiwan Fertility Testing, by End User USD Million (2025-2030)
  • Table 118. Australia Fertility Testing, by Type USD Million (2025-2030)
  • Table 119. Australia Fertility Testing, by End User USD Million (2025-2030)
  • Table 120. Rest of Asia-Pacific Fertility Testing, by Type USD Million (2025-2030)
  • Table 121. Rest of Asia-Pacific Fertility Testing, by End User USD Million (2025-2030)
  • Table 122. Europe Fertility Testing, by Country USD Million (2025-2030)
  • Table 123. Europe Fertility Testing, by Type USD Million (2025-2030)
  • Table 124. Europe Fertility Testing, by End User USD Million (2025-2030)
  • Table 125. Germany Fertility Testing, by Type USD Million (2025-2030)
  • Table 126. Germany Fertility Testing, by End User USD Million (2025-2030)
  • Table 127. France Fertility Testing, by Type USD Million (2025-2030)
  • Table 128. France Fertility Testing, by End User USD Million (2025-2030)
  • Table 129. Italy Fertility Testing, by Type USD Million (2025-2030)
  • Table 130. Italy Fertility Testing, by End User USD Million (2025-2030)
  • Table 131. United Kingdom Fertility Testing, by Type USD Million (2025-2030)
  • Table 132. United Kingdom Fertility Testing, by End User USD Million (2025-2030)
  • Table 133. Netherlands Fertility Testing, by Type USD Million (2025-2030)
  • Table 134. Netherlands Fertility Testing, by End User USD Million (2025-2030)
  • Table 135. Rest of Europe Fertility Testing, by Type USD Million (2025-2030)
  • Table 136. Rest of Europe Fertility Testing, by End User USD Million (2025-2030)
  • Table 137. MEA Fertility Testing, by Country USD Million (2025-2030)
  • Table 138. MEA Fertility Testing, by Type USD Million (2025-2030)
  • Table 139. MEA Fertility Testing, by End User USD Million (2025-2030)
  • Table 140. Middle East Fertility Testing, by Type USD Million (2025-2030)
  • Table 141. Middle East Fertility Testing, by End User USD Million (2025-2030)
  • Table 142. Africa Fertility Testing, by Type USD Million (2025-2030)
  • Table 143. Africa Fertility Testing, by End User USD Million (2025-2030)
  • Table 144. North America Fertility Testing, by Country USD Million (2025-2030)
  • Table 145. North America Fertility Testing, by Type USD Million (2025-2030)
  • Table 146. North America Fertility Testing, by End User USD Million (2025-2030)
  • Table 147. United States Fertility Testing, by Type USD Million (2025-2030)
  • Table 148. United States Fertility Testing, by End User USD Million (2025-2030)
  • Table 149. Canada Fertility Testing, by Type USD Million (2025-2030)
  • Table 150. Canada Fertility Testing, by End User USD Million (2025-2030)
  • Table 151. Mexico Fertility Testing, by Type USD Million (2025-2030)
  • Table 152. Mexico Fertility Testing, by End User USD Million (2025-2030)
  • Table 153. Research Programs/Design for This Report
  • Table 154. Key Data Information from Secondary Sources
  • Table 155. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fertility Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Fertility Testing: by Type USD Million (2018-2023)
  • Figure 6. Global Fertility Testing: by End User USD Million (2018-2023)
  • Figure 7. South America Fertility Testing Share (%), by Country
  • Figure 8. Asia Pacific Fertility Testing Share (%), by Country
  • Figure 9. Europe Fertility Testing Share (%), by Country
  • Figure 10. MEA Fertility Testing Share (%), by Country
  • Figure 11. North America Fertility Testing Share (%), by Country
  • Figure 12. Global Fertility Testing share by Players 2023 (%)
  • Figure 13. Global Fertility Testing share by Players (Top 3) 2023(%)
  • Figure 14. Global Fertility Testing share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 18. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott (United States) Revenue: by Geography 2023
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 22. Siemens Healthineers AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Siemens Healthineers AG (Germany) Revenue: by Geography 2023
  • Figure 24. Beckman Coulter, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Beckman Coulter, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. BioMerieux (France) Revenue, Net Income and Gross profit
  • Figure 27. BioMerieux (France) Revenue: by Geography 2023
  • Figure 28. Church and Dwight (New Jersey) Revenue, Net Income and Gross profit
  • Figure 29. Church and Dwight (New Jersey) Revenue: by Geography 2023
  • Figure 30. DCC (Dubai) Revenue, Net Income and Gross profit
  • Figure 31. DCC (Dubai) Revenue: by Geography 2023
  • Figure 32. Geratherm Medical (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Geratherm Medical (Germany) Revenue: by Geography 2023
  • Figure 34. Germaine Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 35. Germaine Laboratories (United States) Revenue: by Geography 2023
  • Figure 36. Kent Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 37. Kent Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 38. Swiss Precision Diagnostics (China) Revenue, Net Income and Gross profit
  • Figure 39. Swiss Precision Diagnostics (China) Revenue: by Geography 2023
  • Figure 40. Carrot (United States) Revenue, Net Income and Gross profit
  • Figure 41. Carrot (United States) Revenue: by Geography 2023
  • Figure 42. QIAGEN (Netherland) Revenue, Net Income and Gross profit
  • Figure 43. QIAGEN (Netherland) Revenue: by Geography 2023
  • Figure 44. Arva Health (India) Revenue, Net Income and Gross profit
  • Figure 45. Arva Health (India) Revenue: by Geography 2023
  • Figure 46. Ro (United States) Revenue, Net Income and Gross profit
  • Figure 47. Ro (United States) Revenue: by Geography 2023
  • Figure 48. Global Fertility Testing: by Type USD Million (2025-2030)
  • Figure 49. Global Fertility Testing: by Type USD Million (2025-2030)
  • Figure 50. Global Fertility Testing: by End User USD Million (2025-2030)
  • Figure 51. South America Fertility Testing Share (%), by Country
  • Figure 52. Asia Pacific Fertility Testing Share (%), by Country
  • Figure 53. Europe Fertility Testing Share (%), by Country
  • Figure 54. MEA Fertility Testing Share (%), by Country
  • Figure 55. North America Fertility Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Abbott (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Siemens Healthineers AG (Germany)
  • Beckman Coulter, Inc. (United States)
  • bioMerieux (France)
  • Church and Dwight (New Jersey)
  • DCC (Dubai)
  • Geratherm Medical (Germany)
  • Germaine Laboratories (United States)
  • Kent Pharmaceuticals (India)
  • Swiss Precision Diagnostics (China)
  • Carrot (United States)
  • QIAGEN (Netherland)
  • Arva Health (India)
  • Ro (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 226 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fertility Testing Market Quantitative research analysis
Global Fertility Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck KGaA (Germany), Abbott (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Beckman Coulter, Inc. (United States), bioMerieux (France), Church and Dwight (New Jersey), DCC (Dubai), Geratherm Medical (Germany), Germaine Laboratories (United States), Kent Pharmaceuticals (India), Swiss Precision Diagnostics (China), Carrot (United States), QIAGEN (Netherland), Arva Health (India) and Ro (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased used of home-based fertility testing" is seen as one of major influencing trends for Fertility Testing Market during projected period 2023-2030.
The Fertility Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fertility Testing Market Report?

Have a Query? Click Here

Other Related Reports

Ambulance- Comprehensive Study by Type (Advance Life Support (ALS) Ambulance, Basic Life Support (BLS) Ambulance, Mortuary Ambulance, Neonatal Ambulance, Patient Transfer Ambulance, Others), Mode of ...
$ 3800
ECG diagnostics services Comprehensive Study by Application (Hospitals & Clinics, Ambulatory Surgical Centers, Cardiac Centers, Others), Lead (Single-Lead ECG, 3-Lead ECG, 6-Lead ECG, 12-Lead ECG), P...
$ 3800
Needle Free Injection- Comprehensive Study by Type (Fillable Needle-Free Injectors, Prefilled Needle-Free Injectors), Application (Drug Delivery, Vaccines, Cosmetics, Other), Type (Liquid-Based, Proj...
$ 3800
Remote patient monitoring- Comprehensive Study by Components (Service (Cardiovascular Diseases Treatment, Diabetes and Hypertension management, Sleep Disorder Treatment, Weight Management and Fitness...
$ 3800
Spa- Comprehensive Study by Facility Type (Hotel/Resorts Spa, Destination Spa, Day/Salon Spa, Medical Spa, Mineral Spring Spa, Others), Age Group (Up to 18, 19 to 25, 26 to 35, 36 to 55, Above 55), S...
$ 3800